表紙:分子生物学用酵素・キット・試薬市場の規模、シェア、動向分析:製品別、用途別、エンドユーザー別、地域別展望、競合戦略、2030年までのセグメント別予測
市場調査レポート
商品コード
1089966

分子生物学用酵素・キット・試薬市場の規模、シェア、動向分析:製品別、用途別、エンドユーザー別、地域別展望、競合戦略、2030年までのセグメント別予測

Molecular Biology Enzymes & Kits & Reagents Market Size, Share & Trends Analysis By Product, By Application, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

出版日: | 発行: SPER Market Research Pvt. Ltd. | ページ情報: 英文 256 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
分子生物学用酵素・キット・試薬市場の規模、シェア、動向分析:製品別、用途別、エンドユーザー別、地域別展望、競合戦略、2030年までのセグメント別予測
出版日: 2022年06月14日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 256 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の分子生物学用酵素・キット・試薬の市場規模は、今後13.6%のCAGRで拡大し、2030年までに482億1,000万米ドルに達すると予測されています。研究の活発化、投資、ゲノムプロジェクトの増加、ライフサイエンス産業における技術の進歩、遺伝性疾患の発生率の上昇などが、市場拡大の要因となっています。

当レポートでは、世界の分子生物学用酵素・キット・試薬市場について調査し、市場の概要とともに、製品別、用途別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 成長要因、抑制要因、機会、課題の分析
    • 促進要因
    • 抑制要因
    • 市場の機会
    • 課題
  • COVID-19が分子生物学用酵素・キット・試薬市場に及ぼす影響

第5章 市場変数と見通し

  • SWOT分析
  • PESTEL分析
  • ポーターのファイブフォース分析
  • ヒートマップ分析

第6章 分子生物学用酵素・キット・試薬市場、製品別、2019年~2030年(100万米ドル)

  • キットと試薬
  • 酵素
  • ポリメラーゼ
  • リガーゼ
  • 制限酵素
  • 逆転写酵素
  • その他

第7章 分子生物学用酵素・キット・試薬市場、用途別、2019年~2030年(100万米ドル)

  • PCR
  • シーケンシング
  • クローニング
  • エピジェネティクス
  • 制限消化
  • 合成生物学
  • その他

第8章 分子生物学用酵素・キット・試薬市場、エンドユーザー別、2019年~2030年(100万米ドル)

  • 学術研究機関
  • 製薬会社・バイオテクノロジー企業
  • 病院・診断センター
  • その他

第9章 分子生物学用酵素・キット・試薬市場、地域別、2019年~2030年(100万米ドル)

  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ

第10章 企業プロファイル

  • ADS Biotec Inc.
  • Agilent
  • Aldevron
  • Bio Basic
  • Bio-Rad Laboratories Inc
  • Genekam Biotechnology
  • Goldsite Diagnostics Inc.
  • Hangzhou Matridx Biotechnology Co. Ltd.
  • Illumina
  • Integrated DNA Technologies, Inc.
  • Jena Bioscience
  • LGC Biosearch Technologies
  • Lucigen Corporation
  • Merck
  • MoBiTec GmbH
  • Molecular Biology Resources
  • New England Biolabs
  • NZYTech
  • Promega
  • QIAGEN
  • Randox
  • Roche
  • Takara Bio
  • Thermo Fisher
  • Zymo Research Corporation
目次
Product Code: BIOT2232

Global Molecular Biology Enzymes & Kits & Reagents Market projected to be worth USD 48.21 billion by 2030.

According to SPER Market Research, the Molecular Biology Enzymes & Kits & Reagents Market estimated to reach USD 48.21 billion by 2030 with a CAGR of 13.6%. Amplified research, investments, increasing number of genome projects, technological advancement in the life science industry, and growing incidence of genetic disorders; are the fuels for the escalation of the market.

Impact of COVID-19 on the Molecular Biology Enzymes & Kits & Reagents Market

The outbreak of COVID-19 gives a positive impact to the expansion Molecular Biology Enzymes & Kits & Reagents Market.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030
  • Segments covered: By Material, By Technique, By Application, By End-Users, By Region
  • Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa
  • Companies Covered: ADS Biotec Inc., Agilent, Aldevron, Bio Basic, Bio-Rad Laboratories, Inc.¸Genekam Biotechnology, Goldsite Diagnostics Inc., Hangzhou Matridx Biotechnology Co. Ltd., Illumina, Integrated DNA Technologies, Inc., Jena Bioscience, LGC Biosearch Technologies, Lucigen Corporation, Merck, MoBiTec GmbH, Molecular Biology Resources, New England Biolabs, NZYTech, Promega, QIAGEN, Randox, Roche, Takara Bio, Thermo Fisher, Zymo Research Corporation

Driver: increasing number of genome projects

The increasing numeral of genome projects globally, tied with dipping genetic analysis costs; leads to advancement in research in diverse fields like; personalized medicine, microbial genetic, disease treatment. This research need the use of molecular biology enzymes and reagents, consequently impel the expansion of this molecular biology enzymes and kits & reagents market.

Restraints: restricted reimbursements for genetic testing

The inflexible reimbursement policy is the restraints to this market.

Opportunity: Research & Development investments offer significant opportunities for the market

Increase in the funds & grants from the government, advancement in the genomic technological facade, investments in research & development have vast opportunities for this market.

Molecular Biology Enzymes & Kits & Reagents Market, By Product:

Based on the Product, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; Kits & Reagents, Enzymes, Polymerases, Ligases, Restriction Endonucleases, Reverse Transcriptases, Other Enzymes.

Molecular Biology Enzymes & Kits & Reagents Market, By Application:

Based on the Application, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; PCR, Sequencing, Cloning, Epigenetics, Restriction Digestion, Synthetic Biology, Other Applications.

Molecular Biology Enzymes & Kits & Reagents Market, By End User:

Based on the End-Users, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; Academic & Research Institutes, Pharmaceutical & Biotechnology companies, Hospitals & Diagnostic Centers, Other End Users.

Molecular Biology Enzymes & Kits & Reagents Market, By Region:

North America dominates the biggest share of this market; this is due to the increase in funding of translational and clinical research, increasing the figure of pharmaceutical and biotechnology companies, rising investments in research projects in Canada favourable reimbursement scenario.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Molecular Biology Enzymes & Kits & Reagents Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Molecular Biology Enzymes & Kits & Reagents Market, By Product, 2019-2030 (USD Million)

  • 6.1. Kits & Reagents
  • 6.2. Enzymes
  • 6.3. Polymerases
  • 6.4. Ligases
  • 6.5. Restriction Endonucleases
  • 6.6. Reverse Transcriptases
  • 6.7. Other Enzymes

7. Molecular Biology Enzymes & Kits & Reagents Market, By Application, 2019-2030 (USD Million)

  • 7.1. PCR
  • 7.2. Sequencing
  • 7.3. Cloning
  • 7.4. Epigenetics
  • 7.5. Restriction Digestion
  • 7.6. Synthetic Biology
  • 7.7. Other Applications

8. Molecular Biology Enzymes & Kits & Reagents Market, By End User, 2019-2030 (USD Million)

  • 8.1. Academic & Research Institutes
  • 8.2. Pharmaceutical & Biotechnology companies
  • 8.3. Hospitals & Diagnostic Centers
  • 8.4. Other End Users

9. Molecular Biology Enzymes & Kits & Reagents Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. ADS Biotec Inc.
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Agilent
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. Aldevron
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. Bio Basic
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Bio-Rad Laboratories Inc.
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Genekam Biotechnology
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Goldsite Diagnostics Inc.
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Hangzhou Matridx Biotechnology Co. Ltd.
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Illumina
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Integrated DNA Technologies, Inc.
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. Jena Bioscience
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. LGC Biosearch Technologies
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. Lucigen Corporation
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Merck
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. MoBiTec GmbH
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. Molecular Biology Resources
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. New England Biolabs
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. NZYTech
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. Promega
    • 10.19.1. Company details
    • 10.19.2. Financial outlook
    • 10.19.3. Product summary
    • 10.19.4. Recent developments
  • 10.20. QIAGEN
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments
  • 10.21. Randox
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments
  • 10.22. Roche
    • 10.22.1. Company details
    • 10.22.2. Financial outlook
    • 10.22.3. Product summary
    • 10.22.4. Recent developments
  • 10.23. Takara Bio
    • 10.23.1. Company details
    • 10.23.2. Financial outlook
    • 10.23.3. Product summary
    • 10.23.4. Recent developments
  • 10.24. Thermo Fisher
    • 10.24.1. Company details
    • 10.24.2. Financial outlook
    • 10.24.3. Product summary
    • 10.24.4. Recent developments
  • 10.25. Zymo Research Corporation
    • 10.25.1. Company details
    • 10.25.2. Financial outlook
    • 10.25.3. Product summary
    • 10.25.4. Recent developments

9. Molecular Biology Enzymes & Kits & Reagents Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. ADS Biotec Inc.
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Agilent
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. Aldevron
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. Bio Basic
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Bio-Rad Laboratories Inc.
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Genekam Biotechnology
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Goldsite Diagnostics Inc.
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Hangzhou Matridx Biotechnology Co. Ltd.
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Illumina
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Integrated DNA Technologies, Inc.
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. Jena Bioscience
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. LGC Biosearch Technologies
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. Lucigen Corporation
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Merck
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. MoBiTec GmbH
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. Molecular Biology Resources
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. New England Biolabs
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. NZYTech
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. Promega
    • 10.19.1. Company details
    • 10.19.2. Financial outlook
    • 10.19.3. Product summary
    • 10.19.4. Recent developments
  • 10.20. QIAGEN
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments
  • 10.21. Randox
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments
  • 10.22. Roche
    • 10.22.1. Company details
    • 10.22.2. Financial outlook
    • 10.22.3. Product summary
    • 10.22.4. Recent developments
  • 10.23. Takara Bio
    • 10.23.1. Company details
    • 10.23.2. Financial outlook
    • 10.23.3. Product summary
    • 10.23.4. Recent developments
  • 10.24. Thermo Fisher
    • 10.24.1. Company details
    • 10.24.2. Financial outlook
    • 10.24.3. Product summary
    • 10.24.4. Recent developments
  • 10.25. Zymo Research Corporation
    • 10.25.1. Company details
    • 10.25.2. Financial outlook
    • 10.25.3. Product summary
    • 10.25.4. Recent developments